Ecopipam

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Ecopipam
Accession Number
DB12273
Type
Small Molecule
Groups
Investigational
Description

Ecopipam has been used in trials studying the treatment of Tourette's Syndrome, Lesch-Nyhan Disease, Pathological Gambling, and Self-injurious Behavior.

Structure
Thumb
Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Ecopipam Hydrochloride5X1J3190JI190133-94-9APFMVAHRFWBCDG-JUOYHRLASA-N
Categories
UNII
0X748O646K
CAS number
112108-01-7
Weight
Average: 313.83
Monoisotopic: 313.123342
Chemical Formula
C19H20ClNO
InChI Key
DMJWENQHWZZWDF-PKOBYXMFSA-N
InChI
InChI=1S/C19H20ClNO/c1-21-9-8-13-10-16(20)18(22)11-15(13)19-14-5-3-2-4-12(14)6-7-17(19)21/h2-5,10-11,17,19,22H,6-9H2,1H3/t17-,19+/m0/s1
IUPAC Name
(1R,11S)-5-chloro-10-methyl-10-azatetracyclo[9.8.0.0²,⁷.0¹⁴,¹⁹]nonadeca-2,4,6,14,16,18-hexaen-4-ol
SMILES
[H][[email protected]]12CCC3=CC=CC=C3[[email protected]]1([H])C1=CC(O)=C(Cl)C=C1CCN2C

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineEcopipam may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineEcopipam may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
3,4-MethylenedioxyamphetamineEcopipam may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineEcopipam may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Ecopipam.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Ecopipam.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Ecopipam.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Ecopipam.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Ecopipam.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Ecopipam is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Ecopipam.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Ecopipam.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Allopregnanolone is combined with Ecopipam.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Ecopipam.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Ecopipam.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Ecopipam.Approved, Illicit, Investigational
AmisulprideEcopipam may increase the antipsychotic activities of Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Ecopipam.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Ecopipam.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Ecopipam.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Ecopipam.Experimental
AmphetamineEcopipam may decrease the stimulatory activities of Amphetamine.Approved, Illicit, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ecopipam.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Ecopipam.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Ecopipam.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Ecopipam.Investigational, Vet Approved
AzelastineEcopipam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Ecopipam.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Ecopipam.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Ecopipam is combined with Benperidol.Approved, Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Ecopipam.Approved, Investigational
BenzphetamineEcopipam may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Ecopipam.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Ecopipam.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ecopipam.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Ecopipam.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Ecopipam is combined with Bromisoval.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Ecopipam.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Ecopipam is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Ecopipam.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Ecopipam.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Ecopipam.Approved, Investigational
BuprenorphineEcopipam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Ecopipam.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Ecopipam.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Ecopipam.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Ecopipam.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Ecopipam.Approved, Withdrawn
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Ecopipam.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Ecopipam.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Ecopipam.Approved
CanertinibThe risk or severity of adverse effects can be increased when Canertinib is combined with Ecopipam.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Ecopipam.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Ecopipam.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Ecopipam.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Ecopipam.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Ecopipam.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Ecopipam.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Ecopipam.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Ecopipam.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Ecopipam.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Ecopipam.Approved
ChlorphentermineEcopipam may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Ecopipam.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Ecopipam.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Ecopipam.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Ecopipam.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Ecopipam is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Ecopipam.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Ecopipam.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Ecopipam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Ecopipam.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Ecopipam.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Ecopipam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Ecopipam.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Ecopipam is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ecopipam.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Ecopipam.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Ecopipam.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Ecopipam.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Ecopipam.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ecopipam.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Ecopipam is combined with Cyclopropane.Experimental
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Ecopipam.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Ecopipam.Approved, Investigational
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ecopipam.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Dapoxetine.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Ecopipam.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Ecopipam.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Ecopipam.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Ecopipam.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Ecopipam.Vet Approved
DeutetrabenazineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Deutetrabenazine.Approved, Investigational
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ecopipam.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Ecopipam.Approved, Vet Approved
DextroamphetamineEcopipam may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Ecopipam.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Ecopipam.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ecopipam.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Ecopipam.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Ecopipam.Approved, Illicit, Investigational, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Ecopipam is combined with Diethyl ether.Experimental
DiethylpropionEcopipam may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Ecopipam.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ecopipam.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Ecopipam.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Ecopipam.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Ecopipam.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Ecopipam.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ecopipam.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ecopipam.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Ecopipam.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Ecopipam.Approved, Investigational
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Ecopipam.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Ecopipam.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Ecopipam.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ecopipam.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Ecopipam.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Ecopipam.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Ecopipam.Experimental, Illicit
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Ecopipam.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Ecopipam.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Ecopipam is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Ecopipam.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Ecopipam.Approved, Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Ecopipam.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Ecopipam.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Ecopipam.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Ecopipam is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Ecopipam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Ecopipam.Approved, Investigational
EthanolEcopipam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ecopipam.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Ecopipam.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Ecopipam.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Ecopipam.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ecopipam is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Ecopipam.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Ecopipam.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Ecopipam.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Ecopipam.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Ecopipam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Ecopipam.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Ecopipam is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Ecopipam.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Ecopipam.Approved, Investigational
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Ecopipam.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Ecopipam.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ecopipam.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Ecopipam.Approved, Investigational
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Ecopipam.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Ecopipam is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Ecopipam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Ecopipam.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Ecopipam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ecopipam.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Ecopipam.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Ecopipam.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Ecopipam.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Ecopipam.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Ecopipam.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Ecopipam.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Ecopipam.Approved, Illicit, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Ecopipam.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ecopipam.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Ecopipam.Approved, Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Ecopipam.Approved, Illicit, Investigational
GepefrineEcopipam may decrease the stimulatory activities of Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Ecopipam.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Ecopipam.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Ecopipam.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Ecopipam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Ecopipam.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Ecopipam.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Ecopipam.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Ecopipam.Approved
HydrocodoneEcopipam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ecopipam.Approved, Illicit
HydroxyamphetamineEcopipam may decrease the stimulatory activities of Hydroxyamphetamine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ecopipam.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Ecopipam.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Ecopipam.Approved
IndalpineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Indalpine.Investigational, Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Ecopipam is combined with Indiplon.Investigational
Iofetamine I-123Ecopipam may decrease the stimulatory activities of Iofetamine I-123.Approved
IsocarboxazidThe therapeutic efficacy of Ecopipam can be increased when used in combination with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Ecopipam.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Ecopipam.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Ecopipam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Ecopipam.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Ecopipam.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Ecopipam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Ecopipam.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Ecopipam.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Ecopipam.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Ecopipam.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Ecopipam is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ecopipam.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Ecopipam.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Ecopipam.Approved, Investigational
LisdexamfetamineEcopipam may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Ecopipam.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Ecopipam.Illicit
LoprazolamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Ecopipam.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Ecopipam.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Ecopipam.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Ecopipam.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Ecopipam.Approved, Investigational
Magnesium sulfateThe therapeutic efficacy of Ecopipam can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Ecopipam.Approved, Investigational
MebicarThe risk or severity of adverse effects can be increased when Ecopipam is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Ecopipam.Approved
MedazepamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Ecopipam.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Ecopipam.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Ecopipam.Approved, Investigational
MephedroneEcopipam may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineEcopipam may decrease the stimulatory activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Ecopipam.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ecopipam.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Ecopipam is combined with Meptazinol.Experimental
MequitazineEcopipam may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Ecopipam.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Ecopipam.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Ecopipam.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Ecopipam.Approved, Illicit
MethamphetamineEcopipam may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Ecopipam.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Ecopipam.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Ecopipam.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Ecopipam.Approved
MethotrimeprazineEcopipam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Ecopipam.Approved, Investigational, Vet Approved
MethoxyphenamineEcopipam may decrease the stimulatory activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Ecopipam.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Ecopipam.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Ecopipam is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Ecopipam.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Ecopipam.Approved, Investigational
MetyrosineEcopipam may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Ecopipam.Approved, Illicit
MidomafetamineEcopipam may decrease the stimulatory activities of Midomafetamine.Experimental, Illicit, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Ecopipam is combined with Milnacipran.Approved, Investigational
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ecopipam.Approved, Investigational
MirtazapineEcopipam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MMDAEcopipam may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Ecopipam.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Ecopipam.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Ecopipam.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Ecopipam.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Ecopipam.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Ecopipam.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Ecopipam is combined with Nefazodone.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Ecopipam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Ecopipam.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Ecopipam is combined with Norflurane.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Ecopipam.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Ecopipam.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Ecopipam.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Ecopipam.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Ecopipam.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Ecopipam.Approved, Illicit
OrphenadrineEcopipam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Ecopipam.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Ecopipam.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Oxethazaine.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Ecopipam.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Ecopipam.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ecopipam.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Ecopipam.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Ecopipam.Approved
ParaldehydeEcopipam may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Ecopipam is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ecopipam.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Ecopipam.Approved, Investigational, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Ecopipam.Approved
PerazineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Perazine.Approved, Investigational
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Ecopipam.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Ecopipam.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Ecopipam.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Ecopipam.Approved
PhenibutThe risk or severity of adverse effects can be increased when Ecopipam is combined with Phenibut.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Ecopipam.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Ecopipam.Approved
PhentermineEcopipam may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Ecopipam.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Ecopipam.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Ecopipam.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Ecopipam.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Ecopipam is combined with Piritramide.Approved, Investigational
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Ecopipam.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Ecopipam.Approved
PramipexoleEcopipam may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Ecopipam.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Ecopipam.Approved, Illicit
PregabalinThe therapeutic efficacy of Ecopipam can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Ecopipam.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Ecopipam.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Ecopipam.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Ecopipam.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ecopipam.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Ecopipam.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Ecopipam.Approved, Investigational
PropanididThe risk or severity of adverse effects can be increased when Ecopipam is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Ecopipam.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Ecopipam.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Ecopipam.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Ecopipam.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Ecopipam is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Ecopipam.Investigational
PseudoephedrineEcopipam may decrease the stimulatory activities of Pseudoephedrine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Ecopipam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ecopipam.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Ecopipam.Approved, Investigational
QuinisocaineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Ecopipam is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Ecopipam.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Ecopipam.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ecopipam.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ecopipam.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Ecopipam.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Ecopipam.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ecopipam is combined with Ritanserin.Investigational
RitobegronEcopipam may decrease the stimulatory activities of Ritobegron.Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Ecopipam.Approved
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Ecopipam.Vet Approved
RopiniroleEcopipam may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Ecopipam.Approved
RotigotineEcopipam may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Ecopipam.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Ecopipam.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Ecopipam.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Ecopipam.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Ecopipam is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Ecopipam.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Ecopipam.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Ecopipam.Approved
StiripentolThe risk or severity of adverse effects can be increased when Stiripentol is combined with Ecopipam.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ecopipam.Approved, Investigational
SulpirideEcopipam may increase the antipsychotic activities of Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Ecopipam is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Ecopipam.Approved, Investigational
SuvorexantEcopipam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Ecopipam is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Ecopipam.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Ecopipam.Approved, Investigational
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Ecopipam.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Ecopipam.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Ecopipam.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Ecopipam.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Ecopipam.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Ecopipam.Investigational
ThalidomideEcopipam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Ecopipam.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Ecopipam.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Ecopipam.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Ecopipam.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Ecopipam.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Ecopipam is combined with Tiapride.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Ecopipam.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Tilidine.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Ecopipam.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Ecopipam.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Ecopipam.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Ecopipam.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ecopipam.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Ecopipam.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Ecopipam.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tricaine methanesulfonate is combined with Ecopipam.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Ecopipam is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ecopipam.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Ecopipam is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Ecopipam.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Ecopipam.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Ecopipam.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Ecopipam.Approved, Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Ecopipam.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Ecopipam is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Ecopipam.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Ecopipam.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Ecopipam is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Ecopipam.Approved, Investigational
XenonThe risk or severity of adverse effects can be increased when Ecopipam is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Ecopipam.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Ecopipam.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Ecopipam.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Ecopipam is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Ecopipam.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Ecopipam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Ecopipam.Approved, Investigational
ZolpidemEcopipam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Ecopipam.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Ecopipam.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Ecopipam.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Ecopipam.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
107930
PubChem Substance
347828544
ChemSpider
97053
BindingDB
50004823
ChEBI
93645
ChEMBL
CHEMBL298406
Wikipedia
Ecopipam

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentLesch-Nyhan Disease1
1, 2CompletedTreatmentGilles de la Tourette's Syndrome1
2Active Not RecruitingTreatmentGilles de la Tourette's Syndrome1
2CompletedTreatmentPathological Gambling1
2, 3RecruitingTreatmentChildhood-Onset Fluency Disorder / Communication Disorders / Language Disorders / Speech Disorders / Stuttering, Adult1
3TerminatedTreatmentLesch-Nyhan Disease / Self-Injurious Behavior1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0236 mg/mLALOGPS
logP4.28ALOGPS
logP4.07ChemAxon
logS-4.1ALOGPS
pKa (Strongest Acidic)7.5ChemAxon
pKa (Strongest Basic)8.52ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area23.47 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity91.6 m3·mol-1ChemAxon
Polarizability34.7 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzazepines. These are organic compounds containing a benzene ring fused to an azepine ring (unsaturated seven-membered heterocycle with one nitrogen atom replacing a carbon atom).
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzazepines
Sub Class
Not Available
Direct Parent
Benzazepines
Alternative Parents
Tetralins / Azepines / Aralkylamines / 1-hydroxy-2-unsubstituted benzenoids / Aryl chlorides / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds / Organochlorides
show 1 more
Substituents
Benzazepine / Tetralin / 1-hydroxy-2-unsubstituted benzenoid / Azepine / Aralkylamine / Aryl chloride / Aryl halide / Benzenoid / Tertiary amine / Tertiary aliphatic amine
show 11 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 15:47 / Updated on May 02, 2018 01:39